Literature DB >> 12800155

Identification of candidate tumor-suppressor genes in 6q27 by combined deletion mapping and electronic expression profiling in lymphoid neoplasms.

Doris Steinemann1, Stefan Gesk, Yanming Zhang, Lana Harder, Christian Pilarsky, Bernd Hinzmann, Jose Ignacio Martin-Subero, Maria Jose Calasanz, Andrew Mungall, André Rosenthal, Reiner Siebert, Brigitte Schlegelberger.   

Abstract

Deletions in the long arm of chromosome 6 (6q) are among the most frequent chromosome aberrations in lymphoid neoplasms. Recently, the region of minimal deletion (RMD1) in 6q27 was narrowed down to 5-9 Mb. In the present study, we aimed to define the distal border of the commonly lost region in 6q27 more precisely and to identify and investigate tumor-suppressor genes (TSGs) from this region. Twenty-nine cases, in which our previous fluorescence in situ hybridization (FISH) screening that used a set of 36 YAC probes revealed loss in 6q25-27, were further investigated by means of FISH. In all cases, deletions of 6q27 extended from yeast artificial chromosome (YAC) 977e10 spanning the proximal border of RMD1 to the most telomeric YAC 933f7 within the recently established YAC-contig of this region. An interstitial homozygous deletion, flanked by the telomeric probe TelVysion6q and YAC 971g12, was detected, which substantially narrows down the RMD1. To identify candidate TSGs down-regulated in malignant lymphomas from this region of homozygous loss, we performed electronic profiling of expressed sequences mapped to this region. This analysis suggested the gene PDCD2 originally thought to be involved in programmed cell death to be probably down-regulated in malignant B-cell lymphomas compared to normal B lymphocytes. Nevertheless, mutation analyses failed to identify mutations in the coding region of PDCD2 in nine lymphomas with FISH-proved 6q27 deletions. Furthermore, epigenetic studies in these nine and an additional 48 lymphomas did not show altered methylation of the PDCD2 locus in these tumors. Possibly haploinsufficiency is effectual in accelerating tumor progression. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12800155     DOI: 10.1002/gcc.10231

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  18 in total

1.  Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase.

Authors:  Francesco Acquati; Sabrina Bertilaccio; Annalisa Grimaldi; Laura Monti; Raffaella Cinquetti; Paolo Bonetti; Marta Lualdi; Laura Vidalino; Marco Fabbri; Maria Grazia Sacco; Nico van Rooijen; Paola Campomenosi; Davide Vigetti; Alberto Passi; Cristina Riva; Carlo Capella; Francesca Sanvito; Claudio Doglioni; Laura Gribaldo; Paolo Macchi; Antonio Sica; Douglas M Noonan; Paolo Ghia; Roberto Taramelli
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-28       Impact factor: 11.205

2.  Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer.

Authors:  Yan Jia; Yunsheng Yang; Malcolm V Brock; Qimin Zhan; James G Herman; Mingzhou Guo
Journal:  J Pathol       Date:  2013-06       Impact factor: 7.996

3.  PDCD2 controls hematopoietic stem cell differentiation during development.

Authors:  Joseph Kramer; Celine J Granier; Stephani Davis; Katherine Piso; Jane Hand; Arnold B Rabson; Hatem E Sabaawy
Journal:  Stem Cells Dev       Date:  2012-08-16       Impact factor: 3.272

4.  Methylation of DACT2 contributes to the progression of breast cancer through activating WNT signaling pathway.

Authors:  Li Guo; Xiaohong Wang; Yuguang Yang; Hongchun Xu; Zhihong Zhang; Lili Yin; Yan Wang; Maopeng Yang; Shu Zhao; Shuping Bai; Ling Zhao; Zhipeng Wang; Xin Lian; Ying Liu; Qingyuan Zhang
Journal:  Oncol Lett       Date:  2017-12-18       Impact factor: 2.967

5.  PDCD2 is essential for inner cell mass development and embryonic stem cell maintenance.

Authors:  Weipeng Mu; Robert J Munroe; Anna K Barker; John C Schimenti
Journal:  Dev Biol       Date:  2010-09-09       Impact factor: 3.582

6.  Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma.

Authors:  J Schmidt; I Salaverria; A Haake; I Bonzheim; P Adam; S Montes-Moreno; M A Piris; F Fend; R Siebert; L Quintanilla-Martinez
Journal:  Leukemia       Date:  2013-10-23       Impact factor: 11.528

7.  Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas.

Authors:  Beverly W Baron; Nancy Zeleznik-Le; Miriam J Baron; Catherine Theisler; Dezheng Huo; Matthew D Krasowski; Michael J Thirman; Rebecca M Baron; Joseph M Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-27       Impact factor: 11.205

8.  PDCD2 knockdown inhibits erythroid but not megakaryocytic lineage differentiation of human hematopoietic stem/progenitor cells.

Authors:  Natalia A Kokorina; Celine J Granier; Stanislav O Zakharkin; Stephani Davis; Arnold B Rabson; Hatem E Sabaawy
Journal:  Exp Hematol       Date:  2012-08-22       Impact factor: 3.084

9.  PDCD2 functions in cancer cell proliferation and predicts relapsed leukemia.

Authors:  Nora Barboza; Svetlana Minakhina; Daniel J Medina; Binaifer Balsara; Sonya Greenwood; Lien Huzzy; Arnold B Rabson; Ruth Steward; Dale G Schaar
Journal:  Cancer Biol Ther       Date:  2013-06       Impact factor: 4.742

10.  Small regions of overlapping deletions on 6q26 in human astrocytic tumours identified using chromosome 6 tile path array-CGH.

Authors:  K Ichimura; A J Mungall; H Fiegler; D M Pearson; I Dunham; N P Carter; V Peter Collins
Journal:  Oncogene       Date:  2006-02-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.